Published in Blood on May 01, 2001
A phase 1 trial of (90)Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant (2017) 0.75
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Structure of two human beta-actin-related processed genes one of which is located next to a simple repetitive sequence. EMBO J (1983) 3.82
Frzb, a secreted protein expressed in the Spemann organizer, binds and inhibits Wnt-8. Cell (1997) 2.40
Cartilage-derived morphogenetic proteins. New members of the transforming growth factor-beta superfamily predominantly expressed in long bones during human embryonic development. J Biol Chem (1994) 2.03
The adhesion molecule on glia (AMOG) is a homologue of the beta subunit of the Na,K-ATPase. J Cell Biol (1990) 1.87
A 127 kDa component of a UV-damaged DNA-binding complex, which is defective in some xeroderma pigmentosum group E patients, is homologous to a slime mold protein. Nucleic Acids Res (1993) 1.76
Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis. J Biol Chem (1996) 1.70
Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. Br J Haematol (2001) 1.68
The gene encoding L1, a neural adhesion molecule of the immunoglobulin family, is located on the X chromosome in mouse and man. Genomics (1990) 1.67
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation. Ann Oncol (2002) 1.67
Structure of a human beta-actin-related pseudogene which lacks intervening sequences. Nucleic Acids Res (1982) 1.67
High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin Cancer Res (2001) 1.51
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. Proc Natl Acad Sci U S A (1997) 1.45
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
Peripherally inserted central venous catheters for autologous blood progenitor cell transplantation in patients with haematological malignancies. Support Care Cancer (2003) 1.39
Acne fulminans: investigation of acute febrile ulcerative acne. Arch Dermatol (1977) 1.39
A gene expression signature for high-risk multiple myeloma. Leukemia (2012) 1.36
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplant (2006) 1.29
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia (2007) 1.28
Sequence of the cloned Escherichia coli K1 CMP-N-acetylneuraminic acid synthetase gene. J Biol Chem (1989) 1.28
Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma. Bone Marrow Transplant (2005) 1.27
Frog secretions and hunting magic in the upper Amazon: identification of a peptide that interacts with an adenosine receptor. Proc Natl Acad Sci U S A (1992) 1.27
Variant toxin B and a functional toxin A produced by Clostridium difficile C34. FEMS Microbiol Lett (2001) 1.22
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene (2006) 1.21
Identification of cDNA clones of the mouse neural cell adhesion molecule L1. Neurosci Lett (1987) 1.18
Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study. Br J Cancer (2009) 1.17
Cellular UDP-glucose deficiency caused by a single point mutation in the UDP-glucose pyrophosphorylase gene. J Biol Chem (1997) 1.17
A chimeric ribozyme in clostridium difficile combines features of group I introns and insertion elements. Mol Microbiol (2000) 1.16
Association of intercellular adhesion molecule 1 with the multichain high-affinity interleukin 2 receptor. Proc Natl Acad Sci U S A (1990) 1.15
Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood (1994) 1.13
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene (2009) 1.10
Diffuse and banded melanin pigmentation in nails. Arch Dermatol (1972) 1.09
Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia (2002) 1.09
Structural features of a close homologue of L1 (CHL1) in the mouse: a new member of the L1 family of neural recognition molecules. Eur J Neurosci (1996) 1.09
Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci U S A (1992) 1.06
Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high-dose therapy and peripheral blood stem cell transplantation. Br J Haematol (1999) 1.06
Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents. Ann Oncol (2014) 1.05
Frzb-1, an antagonist of Wnt-1 and Wnt-8, does not block signaling by Wnts -3A, -5A, or -11. Biochem Biophys Res Commun (1997) 1.05
Reactions to ionizing radiation. J Am Acad Dermatol (1980) 1.04
Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol (2003) 1.04
Dermatitis associated with an implanted cardiac pacemaker. Arch Dermatol (1970) 1.03
Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation. Leukemia (2010) 1.03
High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant (2004) 1.00
Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging. Int J Cancer (2001) 0.99
High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia (2003) 0.99
Astrocyte-derived TGF-beta 2 and NGF differentially regulate neural recognition molecule expression by cultured astrocytes. J Cell Biol (1991) 0.98
Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev (2002) 0.97
Investigation of the Bacillus cereus phosphonoacetaldehyde hydrolase. Evidence for a Schiff base mechanism and sequence analysis of an active-site peptide containing the catalytic lysine residue. Biochemistry (1988) 0.96
The nucleotide sequences of the actin genes from Saccharomyces carlsbergensis and Saccharomyces cerevisiae are identical except for their introns. J Mol Appl Genet (1981) 0.96
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol (2003) 0.95
[Trichostasis spinulosa. A frequent follicular age-dependent change of the facial skin]. Hautarzt (1975) 0.93
Radiotherapy of skin cancer: modern indications and techniques. Cutis (1976) 0.92
Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet (2006) 0.92
Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study. Ann Oncol (1999) 0.92
A role for Rho in receptor- and G protein-stimulated phospholipase C. Reduction in phosphatidylinositol 4,5-bisphosphate by Clostridium difficile toxin B. Naunyn Schmiedebergs Arch Pharmacol (1996) 0.91
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization. Blood (1994) 0.91
Analysis of p73 and p53 gene deletions in multiple myeloma. Leukemia (1999) 0.90
Comparative, collaborative, and on-site validation of a TaqMan PCR method as a tool for certified production of fresh, campylobacter-free chickens. Appl Environ Microbiol (2006) 0.90
Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant (2001) 0.90
The gene encoding a Prevotella loescheii lectin-like adhesin contains an interrupted sequence which causes a frameshift. J Bacteriol (1992) 0.88
Preoperative elevation of serum C--reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer (2006) 0.88
Identification of a cDNA clone specific for the neural cell adhesion molecule AMOG. J Neurosci Res (1989) 0.88
A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol (1997) 0.88
Analysis of promoter activity and 5' genomic structure of the neural cell adhesion molecule L1. J Neurosci Res (1992) 0.87
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia (2004) 0.87
Immunolocalization of the neural cell adhesion molecule L1 in epithelia of rodents. Cell Tissue Res (1999) 0.86
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant (2007) 0.86
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant (2009) 0.86
Influence of index of individuality on false positives in repeated sampling from healthy individuals. Clin Chem Lab Med (2001) 0.85
UDP-glucose deficiency causes hypersensitivity to the cytotoxic effect of Clostridium perfringens phospholipase C. J Biol Chem (1998) 0.85
Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia (1996) 0.84
The index of individuality is often a misinterpreted quantity characteristic. Clin Chem Lab Med (1999) 0.84
Inflammatory autoimmune neuropathy, presumably induced by bortezomib, in a patient suffering from multiple myeloma. Int J Hematol (2011) 0.84
Bladder necrosis caused by use of THAM in a newborn infant. J Urol (1974) 0.84
Angiogenesis in hematologic malignancies. Ann Hematol (2001) 0.83
Identification of a nucleotide-binding site on glycoprotein IIb. Relationship to ADP-induced platelet activation. J Biol Chem (1991) 0.83
A novel Xenopus homologue of bone morphogenetic protein-7 (BMP-7). Genes Funct (1997) 0.83
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly (2006) 0.83
Characterization of apple 18 and 31 kd allergens by microsequencing and evaluation of their content during storage and ripening. J Allergy Clin Immunol (1995) 0.83
Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant (1999) 0.83
Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta (1994) 0.82
A 439 kb-sized homozygous deletion in 17p13.3 leading to biallelic loss of the ASPA as cause of Canavan disease detected by SNP-array analysis. Mol Genet Metab (2009) 0.82
Exfoliative cytology of human horny layer. Methods of cell removal and microscopic techniques. Arch Dermatol (1967) 0.82
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. Blood (2001) 0.81